Study of ribupatide injection for knee osteoarthritis in people with obesity
Part of Bones, joints & muscles clinical trials.
This study tests an investigational medication called ribupatide, given as an injection, to see if it helps reduce knee pain and improve function in people who have both obesity and knee osteoarthritis. It may also help with weight loss.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- Your body mass index (BMI) is 28 or higher, which indicates obesity.
- You have been trying to manage your weight through diet and exercise for at least 3 months, with your weight staying fairly stable (within about 11 pounds).
- You have been diagnosed with knee osteoarthritis, and an X-ray shows moderate joint changes (grade 2 or 3).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational injection called HRS-4729 to see if it helps people with obesity lose weight. It may offer a new treatment option for those who have been trying to manage their weight with diet and exercise.
This study tests whether an experimental weight-loss injection can reduce knee pain in people who are obese and have knee osteoarthritis. It may help if you have been unable to lose weight through diet and exercise and have moderate knee pain.
This study tests an experimental medicine called KBP-336 for people with both obesity and knee osteoarthritis who still have significant knee pain despite standard treatments. It aims to see if KBP-336 can reduce pain and improve function.
This study tests an injectable medication called Olatorepatide to help people with overweight or obesity lose weight. It is only for people without diabetes who meet specific body mass index (BMI) requirements.
This trial tests if a new medicine, NNC0487-0111, can help people with excess weight and knee osteoarthritis lose weight and reduce knee pain. It is for people who have had knee pain for at least three months and who can stop taking pain relievers for short periods before study visits.
This study checks how different levels of kidney function affect the levels of a new investigational drug called Ribupatide in the blood. It helps doctors understand how the drug works in people with various kidney conditions.
Hear when a new Participants With Obesity and Knee Osteoarthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.